Azura Ophthalmics inks $16 mln Series B
Israel-based Azura Ophthalmics Ltd, a developer of therapies for meibomian gland dysfunction, has closed $16 million in Series B funding. OrbiMed, TPG Biotech and Brandon Capital led the round with participation from return backer Ganot Capital.
10 October 2017•1 min read
